TerminatedNCT01958593
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
Medication studyAges 21+Canada
Understand this study
Who could participate?
Listed age limits: from 21 years.
- Listed locations
- VancouverSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 14, 2014
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 6
- Sponsor
- Resilient Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- Over 21 Years
- Official registry ID
- NCT01958593
- Official title
Show the full official title
A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vancouver
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Resilient Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Placebo and Midomafetamine HCl.
Who can participate?
Listed age limits: from 21 years.
Is this study still recruiting?
The registry lists this study as terminated.
